Headlines about Intercept Pharmaceuticals (NASDAQ:ICPT) have been trending somewhat positive on Saturday, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.2550720390641 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Several equities analysts have issued reports on the company. Oppenheimer reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, May 8th. BidaskClub cut Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 24th. Wedbush restated a “buy” rating and issued a $203.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, May 11th. Cowen restated a “buy” rating and issued a $88.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, May 9th. Finally, ValuEngine cut Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, May 17th. Four analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $125.05.
ICPT stock opened at $85.67 on Friday. Intercept Pharmaceuticals has a 1 year low of $51.05 and a 1 year high of $135.59. The company has a debt-to-equity ratio of -6.88, a quick ratio of 4.58 and a current ratio of 4.58. The company has a market capitalization of $2.49 billion, a P/E ratio of -5.96 and a beta of -1.78.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski purchased 7,812 shares of Intercept Pharmaceuticals stock in a transaction on Monday, April 9th. The shares were bought at an average price of $64.00 per share, with a total value of $499,968.00. Following the purchase, the chief executive officer now directly owns 11,642 shares in the company, valued at approximately $745,088. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Keith Michael Gottesdiener purchased 1,171 shares of Intercept Pharmaceuticals stock in a transaction on Monday, April 9th. The shares were acquired at an average cost of $64.00 per share, for a total transaction of $74,944.00. Following the purchase, the director now owns 5,001 shares in the company, valued at $320,064. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 399,608 shares of company stock worth $25,574,912. 4.90% of the stock is owned by corporate insiders.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.